Company intelligence / Profile preview
ATLyphe
Zürich, Zürich, Switzerlandatlyphe.com ↗
- Ownership
- Private
- Employees
- ~5
- Development stage
- Preclinical
01
Overview
ATLyphe is developing ALY117, a bispecific T cell engager designed to improve the conditioning step in allogeneic hematopoietic stem cell transplantation. The approach aims to selectively eliminate residual leukemic and stem cells with high precision, reducing toxicity compared to chemotherapy-based regimens. This could increase safety, tolerability, and efficacy for patients with blood diseases such as AML. As of 2025, the company remains preclinical with no reported clinical trial results yet.[3][4][5]
- Therapeutic areas
- OncologyHematology
- Modalities
- Bispecific T cell engagersAntibody-based therapies[2][4][6]
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Supported by Wyss Zurich Innovation Hub[4]
Beyond the preview
Go deeper on ATLyphe.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ATLyphe.